Over the previous two and a half years, J&J scientists have rolled up their sleeves alongside companions at argenx to get a more in-depth take a look at the anti-CD70 antibody cusatuzumab, chasing what a prime exec thought of “an vital goal within the biology of choose cancers,” beginning with acute myeloid leukemia.
The pharma big determined it’s time to name it quits.
Cilag — the Janssen subsidiary accountable for this system — is chopping off the collaboration and returning the worldwide business rights to cusatuzumab. With interim Section Ib information in hand, argenx says it would “consider all alternate options to advance” the drug whereas getting ready for the launch of its lead candidate, efgartigimod, at present underneath FDA evaluation.
Preserve studying Endpoints with a free subscription
Unlock this story immediately and be part of 108,000+ biopharma execs studying Endpoints every day — and it is free.